Literature DB >> 29707283

Single agent anti PD-1 inhibitors in esophageal cancer-a first step in a new therapeutic direction.

Elaine M Walsh1, Ronan J Kelly1.   

Abstract

Entities:  

Year:  2018        PMID: 29707283      PMCID: PMC5906338          DOI: 10.21037/jtd.2018.03.43

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.

Authors:  Toshihiro Kudo; Yasuo Hamamoto; Ken Kato; Takashi Ura; Takashi Kojima; Takahiro Tsushima; Shuichi Hironaka; Hiroki Hara; Taroh Satoh; Satoru Iwasa; Kei Muro; Hirofumi Yasui; Keiko Minashi; Kensei Yamaguchi; Atsushi Ohtsu; Yuichiro Doki; Yuko Kitagawa
Journal:  Lancet Oncol       Date:  2017-03-15       Impact factor: 41.316

2.  The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.

Authors:  Ronan J Kelly; Ali H Zaidi; Matthew A Smith; Ashten N Omstead; Juliann E Kosovec; Daisuke Matsui; Samantha A Martin; Christina DiCarlo; E Day Werts; Jan F Silverman; David H Wang; Blair A Jobe
Journal:  Ann Surg       Date:  2018-12       Impact factor: 12.969

Review 3.  A clinical development paradigm for cancer vaccines and related biologics.

Authors:  Axel Hoos; Giorgio Parmiani; Kristen Hege; Mario Sznol; Hans Loibner; Alexander Eggermont; Walter Urba; Brent Blumenstein; Natalie Sacks; Ulrich Keilholz; Geoffrey Nichol
Journal:  J Immunother       Date:  2007-01       Impact factor: 4.456

4.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

Authors:  Kei Muro; Hyun Cheol Chung; Veena Shankaran; Ravit Geva; Daniel Catenacci; Shilpa Gupta; Joseph Paul Eder; Talia Golan; Dung T Le; Barbara Burtness; Autumn J McRee; Chia-Chi Lin; Kumudu Pathiraja; Jared Lunceford; Kenneth Emancipator; Jonathan Juco; Minori Koshiji; Yung-Jue Bang
Journal:  Lancet Oncol       Date:  2016-05-03       Impact factor: 41.316

5.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

6.  Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.

Authors:  Elizabeth D Thompson; Marianna Zahurak; Adrian Murphy; Toby Cornish; Nathan Cuka; Eihab Abdelfatah; Stephen Yang; Mark Duncan; Nita Ahuja; Janis M Taube; Robert A Anders; Ronan J Kelly
Journal:  Gut       Date:  2016-01-22       Impact factor: 23.059

7.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Yoon-Koo Kang; Narikazu Boku; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh; Takaki Yoshikawa; Sang Cheul Oh; Li-Yuan Bai; Takao Tamura; Keun-Wook Lee; Yasuo Hamamoto; Jong Gwang Kim; Keisho Chin; Do-Youn Oh; Keiko Minashi; Jae Yong Cho; Masahiro Tsuda; Li-Tzong Chen
Journal:  Lancet       Date:  2017-10-06       Impact factor: 79.321

8.  Integrated genomic characterization of oesophageal carcinoma.

Authors: 
Journal:  Nature       Date:  2017-01-04       Impact factor: 49.962

9.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

Authors:  Nicholas McGranahan; Andrew J S Furness; Rachel Rosenthal; Sofie Ramskov; Rikke Lyngaa; Sunil Kumar Saini; Mariam Jamal-Hanjani; Gareth A Wilson; Nicolai J Birkbak; Crispin T Hiley; Thomas B K Watkins; Seema Shafi; Nirupa Murugaesu; Richard Mitter; Ayse U Akarca; Joseph Linares; Teresa Marafioti; Jake Y Henry; Eliezer M Van Allen; Diana Miao; Bastian Schilling; Dirk Schadendorf; Levi A Garraway; Vladimir Makarov; Naiyer A Rizvi; Alexandra Snyder; Matthew D Hellmann; Taha Merghoub; Jedd D Wolchok; Sachet A Shukla; Catherine J Wu; Karl S Peggs; Timothy A Chan; Sine R Hadrup; Sergio A Quezada; Charles Swanton
Journal:  Science       Date:  2016-03-03       Impact factor: 47.728

10.  Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.

Authors:  Sarah Derks; Xiaoyun Liao; Anna M Chiaravalli; Xinsen Xu; M Constanza Camargo; Enrico Solcia; Fausto Sessa; Tania Fleitas; Gordon J Freeman; Scott J Rodig; Charles S Rabkin; Adam J Bass
Journal:  Oncotarget       Date:  2016-05-31
  10 in total
  1 in total

1.  Platelet-to-lymphocyte ratio is an independent predictor of chemoradiotherapy-related esophageal fistula in esophageal cancer patients.

Authors:  Dong Han; Jiajia Zhang; Jingjing Zhao; Tongda Lei; Xi Chen; Tian Zhang; Hui Wei; Yong Guan; Jing Wang; Wencheng Zhang; Lujun Zhao; Jun Wang; Zhiyong Yuan; Yongchun Song; Ningbo Liu; Qingsong Pang; Ping Wang
Journal:  Ann Transl Med       Date:  2020-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.